ANAB · AnaptysBio, Inc. · Stock research

Current Thesis

The July trial produced no verdict, and for two weeks the equity was a wait with no timer. That changed on 2026-07-28, when Anaptys and the Tesaro/GSK defendants filed a Joint Stipulation and Proposed Order — approved by the Court — laying out post-trial briefing: opening brief 2026-08-21, answering brief 2026-09-25, reply 2026-10-09, and post-trial oral argument 2026-10-20. The equity has rebuilt with it, from a trough close near $54 on 2026-07-24 to $58.47 on 2026-08-14, RSI(14) 63.6, still 16.2% under the $69.81 adjusted 52-week high. What an investor is buying is a single-question royalty stub: whether a Delaware Vice Chancellor's written opinion returns Jemperli rights to Anaptys. The docket now gives that wait a shape through October; it does not give it a resolution date, because the opinion itself remains unscheduled.

Bullish and bearish views on AnaptysBio, Inc.

The model's bull view on AnaptysBio, Inc. (ANAB), in brief: The wait acquired a calendar. The 2026-07-28 stipulation converted an open-ended post-trial silence into four dated steps ending in oral argument on 2026-10-20. Between 2026-07-24 and 2026-08-14 the stock recovered roughly 8% against that schedule, with no company press release… The bear view: Nothing resolves before late October, and probably not then. Both cases follow in full.

Bull Case

• The wait acquired a calendar. The 2026-07-28 stipulation converted an open-ended post-trial silence into four dated steps ending in oral argument on 2026-10-20. Between 2026-07-24 and 2026-08-14 the stock recovered roughly 8% against that schedule, with no company press release in the window to explain it.
• The royalty is compounding while the case runs. Q1 2026 (released 2026-05-12): collaboration revenue $25.6M, Jemperli royalties $24.7M, up 44% year over year. The disputed asset is growing regardless of who ends up owning the economics.
• April's ruling narrowed the downside case. The 2026-04-24 Chancery decision dismissed Tesaro's anticipatory-breach claim and rejected its royalty-reduction request; the stock rose ~12% on 2026-04-27. Anaptys's own reversion claims survived into the July trial, so the written opinion decides an upside question on top of a preserved rate.
• The burn left the building. The First Tracks spin completed 2026-04-20. TRAX's Q2 2026 release (2026-08-12) reported $168.0M cash and investments at 2026-06-30, R&D of $25.6M for the quarter against $39.3M a year earlier, and runway into Q2 2028 — the clinical spending sits there, not at ANAB.
• A second dated royalty trigger exists. Vanda's imsidolimab carries an FDA action date of 2026-12-12 for generalized pustular psoriasis, with Phase III data published in NEJM Evidence in late April 2026.

Bear Case

• Nothing resolves before late October, and probably not then. The 2026-08-21 filing is a brief, not a decision. Post-trial argument is 2026-10-20 and the Vice Chancellor's written opinion has no scheduled date; Chancery opinions routinely follow argument by weeks to months.
• A bench ruling is not modellable. An adverse opinion removes the reversion option and reopens the royalty-reduction path that April's order closed. No amount of analysis converts that into a distribution.
• The recovery is unexplained by news flow. No Anaptys press release has surfaced after 2026-05-12 in the sources reviewed, and no Q2 2026 results release appeared as of 2026-08-16. The move off $54 is happening on a thin, undocumented bid.
• Sell-side dispersion is extreme. Dated targets run UBS $60 (2026-04-21) and Barclays $63 (2026-04-22) against Leerink $85 (2026-04-28), Piper Sandler $93 (2026-05-04) and HC Wainwright $95 (2026-06-10). A $60-to-$95 band on the same asset is the market saying the litigation, not the royalty, sets the value.
• Single counterparty, single asset. Value rides on GSK's execution of Jemperli. Any deprioritisation or label setback lands with nothing behind it, because the pipeline left with TRAX on 2026-04-20.

Setup & Price Structure

• Reference close 2026-08-14: $58.47. 52-week high $69.81 on the split/dividend-adjusted series (-16.2%); three-month return -7.4%; RSI(14) 63.6.
• The July damage came in two gaps: into roughly $55.76 around 2026-07-14 as the trial opened, then a further ~13% drop on 2026-07-20, with the trough close near $54 on 2026-07-24. The base built off that low has held for three weeks and is what the current level sits on.
• Rising RSI into the low-60s with price still one-sixth below the high describes a repair, not a breakout: the pre-trial shelf in the high-$60s has not been reclaimed.
• The narrative is maturing. The narrative is well known and dated — covered since the 2026-04-24 ruling — and it is still working, with the stock up off the July trough. But flow is moderating: no company headline after 2026-05-12, no dated sell-side action after HC Wainwright on 2026-06-10, and no items in the 30-day news feed reviewed. That is a known situation held by a narrow base, not a fresh one attracting new attention.
• Crowding and positioning observables: no retail-sentiment coverage cluster in the window reviewed; no analyst revision in roughly nine weeks; no insider transactions or equity issuance surfaced; no confirmed upcoming earnings date, since the Q2 2026 release has not appeared in the sources reviewed and Q1 came on 2026-05-12. The inference — stated as inference — is that the August bid is docket-driven rather than flow-driven, and thin bids reverse cheaply.

Catalyst Calendar (next 30 days)

• Beyond the window, on the same schedule: 2026-09-25 defendants' answering brief; 2026-10-09 Anaptys reply brief; 2026-10-20 post-trial oral argument. The written opinion follows at the Court's discretion, with no announced date.
• 2026-12-12 — FDA action date for Vanda's imsidolimab in generalized pustular psoriasis, the next royalty-adding event independent of the litigation.

Elapsed catalysts

• 2026-08-21 — Anaptys opening post-trial brief due, Delaware Court of Chancery. The only dated event inside the window; the brief is a public docket item that shows how Anaptys frames the reversion claim after four days of testimony. (passed 5d ago)
• Not dated: an Anaptys Q2 2026 results release, which had not surfaced in the sources reviewed as of 2026-08-16. (passed 10d ago)

What Would Change Our Mind

The structural break is the base that formed off the 2026-07-24 trough near $54 giving way — that base is the entire evidence that the docket schedule restored a bid. A weekly close below $52 removes it and reads as the market discounting an adverse opinion rather than waiting for one. Two non-price conditions do the same work: the 2026-10-20 post-trial argument coming and going with the written opinion still unscheduled into year-end, which returns the equity to the dateless drift that produced the July unwind; and any post-trial opinion denying reversion, which ends the thesis outright at whatever price it lands on. On the other side, a company disclosure that Jemperli royalties continued the Q1 trajectory — $24.7M, +44% year over year — would strengthen the annuity leg independent of the ruling.

Correlation Notes

• ANAB does not trade with the biotech tape in any usable way; its two largest 2026 moves (+12% on 2026-04-27, ~-13% on 2026-07-20) were both Delaware docket events. Sector ETFs are a poor hedge and a poor read-through.
• The closest live comparable is GSK's Jemperli disclosure: the royalty base is GSK product sales, so GSK quarterly oncology detail is the fundamental input that moves the asset's value while the ownership question is litigated.
• TRAX is the spin sibling and shares nothing economically after 2026-04-20 — its 2026-08-12 Q2 print (cash $168.0M, runway into Q2 2028) tells a reader where the clinical risk went, and its price action carries no information about ANAB's royalty book.
• Royalty-company peers (the cohort HC Wainwright convened at its 2026-05-06 royalty conference, which Anaptys's CEO attended) are the valuation frame the sell-side is using for the post-litigation state, not for the current one.